Download PDF
Thromb Haemost 1989; 62(04): 1074-1077
DOI: 10.1055/s-0038-1647120
Original Article
Coagulation
Schattauer GmbH Stuttgart

Alpha-2-Macroglobulin Is an Important Progressive Inhibitor of Thrombin in Neonatal and Infant Plasma

Barbara Schmidt
The Departments of Pediatrics and Pathology, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada
,
Lesley Mitchell
The Departments of Pediatrics and Pathology, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada
,
Frederick A Ofosu
The Departments of Pediatrics and Pathology, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada
,
Maureen Andrew
The Departments of Pediatrics and Pathology, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 21 December 1988

Accepted after revision 01 September 1989

Publication Date:
24 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Antithrombin III (ATIII) is the main inhibitor of thrombin in adult plasma; α2-macroglobulin (α2M) and heparin cofactor II (HCII) are of lesser importance. The relative contributions of these inhibitors to the inactivation of thrombin may differ during the neonatal period and infancy, when plasma concentrations of α2M are about twice as high as those of ATIII. We therefore compared the relative importance of these anti-proteases for the inhibition of 125I-thrombin in defibrinated pooled adult and neonatal plasma. Observations were also made in pooled plasma of 6 months old infants. 125I-thrombin-inhibitor complexes were quantitated after SDS-PAGE and autoradiography by scanning densitometry. Thrombin (2.5 NIH U/ml) was inhibited more slowly in neonatal than in adult plasma. However, both plasmas inhibited 88% of the added thrombin by 5 minutes. α2M inhibited consistently a larger fraction of thrombin in neonatal than in adult plasma. Consequently, the ratio of thrombin bound to ATIII over thrombin bound to α2M was significantly lower in neonatal (<2.5) than in adult plasma (>4.5; p <0.0001). In infant plasma, this ratio was <2.0. Upon addition of therapeutic amounts of heparin (0.4 U/ml), differences between the contributions of ATIII and α2M to the inhibition of thrombin were no longer apparent, as over 90% of complexed thrombin was bound to ATIII in heparinized plasmas of all age groups. We conclude that α2M is an important progressive inhibitor of thrombin in young infants. This finding may explain why healthy newborns rarely suffer from thrombosis, despite their low plasma ATIII levels.

Keywords

Alpha-2-macroglobulin - Antithrombin III - Newborn
 

  • References

  • 1 Abildgaard U. Purification of two progressive antithrombins of human plasma. Scand J Clin Lab Invest 1967; 19: 190-195
    CrossrefPubMedGoogle Scholar
  • 2 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505
    PubMedGoogle Scholar
  • 3 Steinbuch M, Blatrix C, Josso F. α2-Macroglobulin as progressive antithrombin. Nature 1967; 216: 500-501
    CrossrefPubMedGoogle Scholar
  • 4 Lane JL, Bird B, Rizza CR. A new assay for the measurement of total progressive antithrombin. Br J Haematol 1975; 30: 103-115
    CrossrefPubMedGoogle Scholar
  • 5 Shapiro SS, Anderson DB. Thrombin inhibition in normal plasma. In: Chemistry and Biology of Thrombin. Lundblad RL, Fenton JW, Mann KG. Eds Ann Arbor Science Publishing; Ann Arbor, MI: 1977: 361-374
    Google Scholar
  • 6 Schmidt B, Zipursky A. Thrombotic disease in newborn infants. Clin Perinatal 1984; 11: 461-468
    CrossrefPubMedGoogle Scholar
  • 7 Ganrot PO, Schersten B. Serum α2-macroglobulin concentration and its variation with age and sex. Clin Chim Acta 1967; 15: 113-120
    CrossrefPubMedGoogle Scholar
  • 8 Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers T. The development of the human coagulation system in the fullterm infant. Blood 1987; 70: 165-172
    PubMedGoogle Scholar
  • 9 Fischer AM, Thpon-Bretaudiere J, Bros A, Josso F. Respective roles of antithrombin III and alpha 2 macroglobulin in thrombin inactivation. Thromb Haemostas 1981; 45: 051-054
    PubMedGoogle Scholar
  • 10 Ofosu FA, Modi GJ, Smith LM, Cerskus AL, Hirsh J, Blajchman M. Heparin sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984; 64: 742-747
    PubMedGoogle Scholar
  • 11 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II: Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2165
    PubMedGoogle Scholar
  • 12 Marchalonis JJ. An enzymic method for the trace iodination of immuno-globulins and other proteins. Biochem J 1969; 113: 299-305
    CrossrefPubMedGoogle Scholar
  • 13 Fernandez FA, Buchanan MR, Hirsh J, Fenton II JW. Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits. Thromb Haemostas 1987; 57: 286-293
    PubMedGoogle Scholar
  • 14 SAS/STAT Guide for personal computers. Version 6, SAS Institute Inc.; Cary, NC: 1985
    Google Scholar
  • 15 Schmidt B, Mitchell L, Brooker LA, Ofosu FA, Andrew M. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989; 25: 405-408
    CrossrefPubMedGoogle Scholar
  • 16 McDonald MM, Hathaway WE. Anticoagulant therapy by continuous heparinization in newborn and older infants. J Pediatr 1982; 101: 451-457
    CrossrefPubMedGoogle Scholar
  • 17 Schmidt B, Buchanan MR, Ofosu F, Brooker LA, Hirsh J, Andrew M. Antithrombotic properties of heparin in a neonatal piglet model of thrombin induced thrombosis. Thromb Haemostas 1988; 60: 289-292
    PubMedGoogle Scholar